Intercept Drug Ocaliva Passed the Test

Another day, another badly needed treatment for a dangerous disease is on its way to be FDA approved. The day was yesterday, Thursday, April 7, 2016. The company is Intercept (ICPT), the disease is primary biliary cirrhosis renamed primary biliary cholangitis (PBC), the drug is called Ocaliva™ (obeticholic acid). The good news came from the FDA's Gastrointestinal Drugs Advisory Committee, which voted 17 to 0to recommend accelerated approval of Ocaliva™.   

Now the expected FDA action to grant the definitive approval under the Prescription Drug User Fee . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.